Diseases /
Diffuse Astrocytoma
Back to Diseases List
Overview
NCI Definition: A low-grade (WHO grade II) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified. [1]
Clinical Trials
There are 8 clinical trials for diffuse astrocytoma, of which 8 are open and 0 are completed or closed. Of the trials that contain diffuse astrocytoma as an inclusion criterion, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open).
EGFR, IDH1, and IDH2 are the most frequent gene inclusion criteria for diffuse astrocytoma clinical trials [3].
Radiation therapy, temozolomide, and cc-90010 are the most common interventions in diffuse astrocytoma clinical trials.
Significant Genes in Diffuse Astrocytoma
EGFR +
EGFR is an inclusion eligibility criterion in 2 clinical trials for diffuse astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and diffuse astrocytoma as inclusion criteria, 2 are phase 2 (2 open) [3].
IDH1 +
IDH1 is an inclusion eligibility criterion in 2 clinical trials for diffuse astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and diffuse astrocytoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].
IDH2 +
IDH2 is an inclusion eligibility criterion in 2 clinical trials for diffuse astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and diffuse astrocytoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].
TERT +
TERT is an inclusion eligibility criterion in 2 clinical trials for diffuse astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain TERT status and diffuse astrocytoma as inclusion criteria, 2 are phase 2 (2 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
